Chair: Rifaat Safadi, Hadassah Hebrew University, Israel
& Lawrence Serfaty, University of Strasbourg, France

08:30 - 08:50
Psychology point of view – behavioural aspects
Maya Balakrishnan, Baylor College of Medicine, USA

08:50 - 09:10
Apps to support activity and lifestyle change – the use of technology
Michael Trenell, Newcastle University, UK

09:10 - 09:30
Current state of the art: Weight loss therapy
Raluca Pais, Pitié Salpetriere Hospital, France

09:30 - 09:50
Current state of the art: Surgical weight loss
Gerhard Prager, Medical University of Vienna, Austria

09:50 - 10:00
Liver saturated fat content associates with hepatic DNA methylation in obese individuals
Ratika Sehgal, University of Eastern Finland, Finland

10:00 - 10:30
Panel Discussion

Optimising management and prevention of end organ damage

Chairs: Vlad Ratziu, Sorbonne University, France
& Quentin Anstee, Newcastle University, UK

11:00 - 11:20
Focus on diabetes therapy
Michael Roden, German Diabetes Center, Germany

11:20 - 11:40
Focus on atherogenic dyslipidaemia
Kathleen Corey, Harvard Medical School, USA

11:40 - 12:00
Focus on chronic kidney disease
Gianluca Perseghin, Università degli Studi Milano Bicocca, Italy

12:00 - 12:10
Lanifibranor, a pan-PPAR agonist, improves markers of cardiometabolic health in patients with NASH
Michael Cooreman, France

12:10 - 12:35
Panel Discussion

Industry session not included in the main event CME/CPD credit

Chairs: Arun Sanyal, Virginia Commonwealth University, USA
& Quentin Anstee, Newcastle University, UK

14:20 - 14:40
Evaluation of NAFLD in a large public health system (population screening)
Lawrence Serfaty, University of Strasbourg, France

14:40 - 15:00
How to identify the patients with NASH stage 2 and 3
Jerome Boursier, CHU d'Angers, France

15:00 - 15:20
How to identify patients with cirrhosis
Jörn Schattenberg, University Medical Center Mainz, Germany

15:20 - 15:40
How to identify alcohol use disorder in your patients
Philippe Mathurin, University Hospital of Lille, France

15:40 - 15:50
NAFLD and insulin resistance in type 1 diabetes. Time to expand the criteria of the metabolic syndrome?
Jonathan Mertens, University of Antwerp, Belgium

15:50 - 16:00
Significantly worse outcomes after variceal haemorrhage for cirrhosis patients with prior NASH versus those without in the TriNetX EHR database
Philip Ambery, Addenbrooke’s Hospital, Sweden

16:00 - 16:30
Panel Discussion

Chair: Arun Sanyal, Virginia Commonwealth University, USA

Trial endpoints – balancing short-term gain with long-term pain
Quentin Anstee, Newcastle University, UK

Chair: Philippe Mathurin, University Hospital of Lille, France
& Jörn Schattenberg, University Medical Center Mainz, Germany

17:30 - 17:50
The Impact of NAFLD on COVID related outcomes
Rakhi Mailwall, Institute of Liver & Biliary Sciences, India

17:50 - 18:10
The impact of the pandemic on liver related care
Sidney Barritt, The University of North Carolina at Chapel Hill, USA

18:10 - 18:30
Impact of fatty liver disease on COVID19 vaccination
Rifaat Safadi, Hadassah Hebrew University, Israel

18:30 - 19:00
Panel Discussion

Chairs: Arun Sanyal, Virginia Commonwealth University, USA
& Michael Roden, German Center of Diabetology, Germany

08:30 - 08:50
GLP1 containing combinations – a rationale for therapies in NASH
Amalia Gastaldelli, National Research Council of Italy, Italy

08:50 - 09:10
Clinical use of GLP1 in NASH
Philip Newsome, University of Birmingham, UK

09:10 - 09:30
FGF21 Pharmacology in the context of NASH
Saswata Talukdar, CMD Discovery, USA

09:30 - 09:40
A novel positive allosteric modulator of the GABAA receptor prevents lipotoxicity-induced liver cell injury
Juergen Eckel, Institute for Clinical Diabetology, Germany

09:40 - 10:10
Panel Discussion

Chairs: Quentin Anstee, Newcastle University, UK
& Rifaat Safadi, Hadassah Hebrew University, Israel

10:40 - 11:00
Bile Acid and bile acid conjugates
Arun Sanyal, Virginia Commonwealth University, USA

11:00 - 11:20
Thyroxine beta receptors
Stephen Harrison, Pinnacle Clinical Research, USA

11:20 - 11:40
PPAR agonists biology
Sven Francque, University of Antwerp, Belgium

11:40 - 12:00
Gut microbiota and NAFLD: gut-liver axis
Oxana Drapkina, National Medical Research Center for Therapy and Preventive Medicine, Russian Federation

12:00 - 12:10
Antagonizing sodium taurocholate co-transporting polypeptide (NTCP) on NK cells from NAFLD patients elevate their activity and mediate activated hepatic stellate cells killing
Johnny Amer, Hadassah Hospital, Israel

12:10 - 12:40
Panel Discussion

Quentin Anstee, Newcastle University, UK
Oxana Drapkina, National Medical Research Center for Therapy and Preventive Medicine, Russian Federation
Michael Roden, German Diabetes Center, Germany
Rifaat Safadi, Hadassah Hebrew University, Israel
Arun Sanyal, Virginia Commonwealth University, USA